Get the Stockscreener App
0.6668
0.92%
-0.0062
After Hours:
.67
0.0032
+0.48%
Lantern Pharma Inc stock is traded at $0.6668, with a volume of 231.27K.
It is down -0.92% in the last 24 hours and down -60.78% over the past month.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
See More
Previous Close:
$0.673
Open:
$0.66
24h Volume:
231.27K
Relative Volume:
0.88
Market Cap:
$9.96M
Revenue:
Net Income/Loss:
$-15.91M
P/E Ratio:
-0.4615
EPS:
-1.445
Net Cash Flow:
$-15.07M
1W Performance:
-19.66%
1M Performance:
-60.78%
6M Performance:
-72.45%
1Y Performance:
-84.91%
1-Day Range:
$0.6551
$0.7055
1-Week Range:
$0.651
$0.85
52-Week Range:
$0.651
$4.58
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
0.6668 | 9.96M | 0 | -15.91M | -15.07M | -1.445 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
A reported Lantern Pharma (LTRN) stake includes 212,554 shares issuable through warrants. - Stock Titan
Form PRE 14A LANTERN PHARMA INC. For: 10 October By Investing.com - Investing.com South Africa
Lantern Pharma Schedules Virtual 2026 Annual Meeting with Seven Key Proposals on December 1 - Kalkine Media
With 281,597 shares unissued and unreserved, Lantern Pharma (LTRN) proposes a higher share limit. - Stock Titan
More than half of Taiwan’s lung cancer patients never smoked. A trial site there is screening patients. - Stock Titan
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance Australia
Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance UK
After 30 business days below Nasdaq's value minimum, Lantern Pharma (NASDAQ: LTRN) has time to comply. - Stock Titan
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering - BioSpace
Lantern Pharma closes $4 million stock offering By Investing.com - Investing.com South Africa
Lantern Pharma closes $4 million stock offering By Investing.com - Investing.com Canada
Lantern Pharma closes $4 million stock offering By Investing.com - Investing.com Nigeria
Lantern Pharma closes $4 million stock offering - Investing.com
Lantern Pharma closes $4 million stock offering By Investing.com - Investing.com India
Lantern Pharma Raises $4.0 Million in Registered Direct; Issues Warrants, Engages Rodman & Renshaw - TradingView
Lantern Pharma closes $4 million stock offering By Investing.com - Investing.com UK
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering - Business Wire
Form 424B5 Lantern Pharma Inc For: 30 September By Investing.com - Investing.com South Africa
Form 424B5 Lantern Pharma Inc For: 30 September By Investing.com - Investing.com Nigeria
Form 424B5 Lantern Pharma Inc For: 30 September By Investing.com - Investing.com Canada
Lantern Pharma raises $4M in registered direct offering - Investing.com
Lantern Pharma announces up to $8M registered direct offering - TradingView
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering - Business Wire
Lantern Pharma Inc. (LTRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Lantern Pharma Inc For: 24 September By Investing.com - Investing.com Nigeria
Form 8K Lantern Pharma Inc For: 24 September By Investing.com - Investing.com India
Form 8K Lantern Pharma Inc For: 24 September By Investing.com - Investing.com UK
Form 8K Lantern Pharma Inc For: 23 September By Investing.com - Investing.com Nigeria
Form 8K Lantern Pharma Inc For: 23 September By Investing.com - Investing.com UK
A cancer drug could gain patent protection through 2042. Lantern Pharma’s LP-284 targets two blood cancers. - Stock Titan
Lantern Pharma Inc (NASDAQ: LTRN) Share Price, LTRN Stock News, LTRN Share Price & Updates - kalkine.ca
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript - benzinga.com
Lantern Pharma Share PriceLTRN, RNS News, Articles, Quotes, & Charts (NASDAQ:LTRN) - Proactive financial news
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) - guardonline.com
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) - 富途牛牛
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) - Yahoo Finance
Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe
Lantern Pharma Earnings Call: AI Spinout, Trial Momentum - TipRanks
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - AOL.com
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - The Globe and Mail
Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Sahm
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI - GuruFocus
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ... - Yahoo Finance
Lantern Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Lantern Pharma Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
Lantern Pharma (LTRN) Slides 2.26% as Biotech Stock Approaches Critical $2.46 SupportKey Reversal Day - vinanet.vn
Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark - GuruFocus
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceBull Pennant - vinanet.vn
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceFRAMA Signal - dars.gov.et
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceVolume Profile - careplusvn.com
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KEYSER D JEFFREY | Director |
May 12 '26 |
Buy |
2.06 |
48,544 |
100,001 |
94,303 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):